Bioventus price target raised to $15 from $12 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on Bioventus (BVS) to $15 from $12 and keeps a Buy rating on the shares. The firm said they posted a strong Q3, beating revenue, adj. EBITDA, and pro forma EPS expectations. It saw double-digit growth in both its Pain Treatments and Surgical Solutions businesses while continuing improved sales force execution in its Exogen business.